Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Karel Hählen"'
Autor:
A H Loonen, Christian M. Zwaan, Bianca F. Goemans, Dirk Reinhardt, Karel Hählen, Gertjan J.L. Kaspers, Amy Harlow, Brenda Gibson, Ursula Creutzig, Michael Heinrich
Publikováno v:
Blood, 106(10), 3532-3537. American Society of Hematology
Goemans, B F, Zwaan, C M, Harlow, A, Loonen, A H, Gibson, B E S, Hählen, K, Reinhardt, D, Creutzig, U, Heinrich, M C & Kaspers, G J L 2005, ' In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets ', Blood, vol. 106, no. 10, pp. 3532-3537 . https://doi.org/10.1182/blood-2005-04-1640
Goemans, B F, Zwaan, C M, Harlow, A, Loonen, A H, Gibson, B E S, Hählen, K, Reinhardt, D, Creutzig, U, Heinrich, M C & Kaspers, G J L 2005, ' In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets ', Blood, vol. 106, no. 10, pp. 3532-3537 . https://doi.org/10.1182/blood-2005-04-1640
Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities
Autor:
R. Släter, Anjo J.P. Veerman, Martin Zimmermann, Rob Pieters, Karel Hählen, D. R. Huismans, Jochen Harbott, Gertjan J.L. Kaspers, Christian M. Zwaan, U. Creutzig
Publikováno v:
Blood, 100, 3352-3360. American Society of Hematology
Blood, 100(9), 3352-3360. American Society of Hematology
Zwaan, C M, Kaspers, G J L, Pieters, R, Hählen, K, Huismans, D R, Zimmermann, M, Harbott, J, Slater, R M, Creutzig, U & Veerman, A J P 2002, ' Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities ', Blood, vol. 100, no. 9, pp. 3352-3360 . https://doi.org/10.1182/blood.V100.9.3352
Blood, 100(9), 3352-3360. American Society of Hematology
Zwaan, C M, Kaspers, G J L, Pieters, R, Hählen, K, Huismans, D R, Zimmermann, M, Harbott, J, Slater, R M, Creutzig, U & Veerman, A J P 2002, ' Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities ', Blood, vol. 100, no. 9, pp. 3352-3360 . https://doi.org/10.1182/blood.V100.9.3352
Specific cytogenetic abnormalities predict prognosis in childhood acute myeloid leukemia (AML). However, it is unknown why they are predictive and whether this is related to drug resistance. We previously reported that Down syndrome (DS) AML was asso
Autor:
A. E. J. Duyn, A. J. P. Veerman, C. H. Van Zantwijk, Gertjan J.L. Kaspers, Karel Hählen, Rob Pieters, G. J. Broekema
Publikováno v:
Annals of Hematology, 78, 163-171. Springer-Verlag
Annals of Hematology, 78(4), 163-171. Springer Verlag
Duyn, A E J, Kaspers, G J L, Pieters, R, Van Zantwijk, C H, Broekema, G J, Hählen, K & Veerman, A J P 1999, ' Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia ', Annals of Hematology, vol. 78, no. 4, pp. 163-171 . https://doi.org/10.1007/s002770050495
Annals of Hematology, 78(4), 163-171. Springer Verlag
Duyn, A E J, Kaspers, G J L, Pieters, R, Van Zantwijk, C H, Broekema, G J, Hählen, K & Veerman, A J P 1999, ' Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia ', Annals of Hematology, vol. 78, no. 4, pp. 163-171 . https://doi.org/10.1007/s002770050495
Growth factors have been reported to enhance the cytotoxicity of anticancer agents. In our study we investigated the capacities of interleukin 3 (IL-3), interleukin 7 (IL-7), low-molecular-weight B-cell growth factor (Imw-BCGF), and IL-3 + 7 to induc
Autor:
G. J. Broekema, A. H. Loonen, M. W. Heyenbrok, Rob Pieters, D. R. Huismans, Karel Hählen, M. W.J. Dirven, Anjo J.P. Veerman
Publikováno v:
Blood. 76:2327-2336
The knowledge about drug resistance in childhood leukemias and acute lymphoblastic leukemia (ALL) in general is limited. This is because of the lack of a suitable in vitro drug sensitivity assay, which is in part due to low in vitro ALL cell survival
Autor:
Ursula Creutzig, E. R. Van Wering, Ch. M. Zwaan, D. R. Huismans, Rob Pieters, A. J. P. Veerman, G. J. L. Kaspers, Karel Hählen
Publikováno v:
Haematology and Blood Transfusion Hämatologie und Bluttransfusion ISBN: 9783642639494
The prognostic influence of age in childhood acute myeloid leukemia (AML) is less clear as in childhood acute lymphoblastic leukemia (ALL), where infants carry a poor prognosis. Reports on outcome in infant AML have been contradictory, and also the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff127f82b0209aacb7ce916fb4067307
https://doi.org/10.1007/978-3-642-59358-1_47
https://doi.org/10.1007/978-3-642-59358-1_47
Autor:
Karel Hählen, Gritta Janka-Schaub, Anjo J.P. Veerman, Christian M. Zwaan, D. R. Huismans, Christina H. van Zantwijk, Gerrit Jansen, Godefridus J. Peters, Esther de Vries, Gertjan J.L. Kaspers, Ursula Creutzig, Marianne G. Rots, Rob Pieters
Publikováno v:
Blood, 99(1), 245-251. AMER SOC HEMATOLOGY
Blood, 99(1), 245-251. American Society of Hematology
Blood, 99(1), 245-51. American Society of Hematology
Zwaan, C M, Kaspers, G J L, Pieters, R, Hählen, K, Janka-Schaub, G E, van Zantwijk, C H, Huismans, D R, de Vries, E, Rots, M G, Peters, G J, Jansen, G, Creutzig, U & Veerman, A J P 2002, ' Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome ', Blood, vol. 99, no. 1, pp. 245-51 .
Blood, 99(1), 245-251. American Society of Hematology
Blood, 99(1), 245-51. American Society of Hematology
Zwaan, C M, Kaspers, G J L, Pieters, R, Hählen, K, Janka-Schaub, G E, van Zantwijk, C H, Huismans, D R, de Vries, E, Rots, M G, Peters, G J, Jansen, G, Creutzig, U & Veerman, A J P 2002, ' Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome ', Blood, vol. 99, no. 1, pp. 245-51 .
Children with Down syndrome (DS) have an increased risk for leukemia. The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL. D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b9400f1149ea8f358b8388876630bb
https://research.rug.nl/en/publications/f0ea9517-13e0-41df-bf8b-09c9321c1adf
https://research.rug.nl/en/publications/f0ea9517-13e0-41df-bf8b-09c9321c1adf
Autor:
A. J. P. Veerman, Gertjan J.L. Kaspers, C. H. Van Zantwijk, R. Pieters, G. J. Broekema, Eric G. Haarman, Karel Hählen
Publikováno v:
Drug Resistance in Leukemia and Lymphoma III ISBN: 9781461371809
The antileukemic activity of cytotoxic drugs is increasingly thought to be the result of induction of apoptosis. Several proto-oncogenes have been related to the regulation of this process. In this study we evaluated the relation between bcl-2 expres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1723e930526b23d9af4ea42f538ca697
https://doi.org/10.1007/978-1-4615-4811-9_35
https://doi.org/10.1007/978-1-4615-4811-9_35
Autor:
Gertjan J.L. Kaspers, E. Klumper, Elisabeth R. van Wering, Karel Hählen, Günter Henze, Reinhard Hartmann, Anjo J.P. Veerman, D. R. Huismans, A. H. Loonen, Rob Pieters
Publikováno v:
Klumper, E, Pieters, R, Veerman, A J P, Huismans, D R, Loonen, A H, Hählen, K, Kaspers, G J L, Van Wering, E R, Hartmann, R & Henze, G 1995, ' In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia ', Blood, vol. 86, no. 10, pp. 3861-3868 . https://doi.org/10.1182/blood.v86.10.3861.bloodjournal86103861
Blood, 86(10), 3861-3868. American Society of Hematology
Blood, 86(10), 3861-3868. American Society of Hematology
Cellular drug resistance is thought to be an important cause of the poor prognosis for children with relapsed or refractory acute lymphoblastic leukemia (ALL), but it is unknown when, to which drugs, and to what extent resistance is present. We deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da34707f411da2b0cfedab87d901b628
https://research.vumc.nl/en/publications/fa5ecbe1-2e4a-4278-ba6c-ccfa774c7c83
https://research.vumc.nl/en/publications/fa5ecbe1-2e4a-4278-ba6c-ccfa774c7c83
Autor:
A H Loonen, Gertjan J.L. Kaspers, Brenda Gibson, Dirk Reinhardt, Christian M. Zwaan, Karel Hählen, Ursula Creutzig, Bianca F. Goemans, Jacqueline Cloos, Susanne J. H. Vijverberg
Publikováno v:
Blood. 106:107-107
Gemtuzumab ozogamicin (GO or Mylotarg®) is increasingly being used in the treatment of AML. GO consists of a cytotoxic drug - calicheamicin which is conjugated to an anti-CD33 antibody. Most AML patients highly express CD33 on their blasts. Studies
Publikováno v:
Pediatric Hematology and Oncology. 5:93-102
A pilot study was undertaken to determine the efficacy of remission induction therapy with 1000 mg/m2 high-dose cytosine-arabinoside (one i.v. push injection every 24 h, days 1-12), 65 mg/m2 6-thioguanine (orally, days 1-12), and 40 mg/m2 doxorubicin